Anti-Viral Drugs Market with Current Trends Analysis, 2016-2026 Anti-Viral Drugs Market with Current Trends Analys | Page 6

Report
Description
Report Description
people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries
with a high burden of HIV, two out of three people in need are receiving treatment, and
two out of three positive pregnant women are receiving antiretroviral drugs to prevent
HIV transmission to their infants.
Anti-viral Drugs Market: Regional Overview
Region wise, the global anti-viral drugs market is classified into regions namely, North
America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East
and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or
China, the death rate among people living with HIV has decreased by 80%. In 2015, in
India the number of people living with HIV were 2.1 Mn and in U.S. the number was
around 1.2 Mn in the year 2013.
Browse Full Report@
http://www.futuremarketinsights.com/reports/anti-viral-drugs-market

Anti-viral Drugs Market: Key Players
Some of the key players in global anti-viral drugs market, which are focusing on general
molecular mechanisms of antiviral drugs rather than therapies for individual viruses,
include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca,
Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.